acyclovir and 3-bromo-5-22-23-trihydroxystigmastan-6-one

acyclovir has been researched along with 3-bromo-5-22-23-trihydroxystigmastan-6-one* in 1 studies

Other Studies

1 other study(ies) available for acyclovir and 3-bromo-5-22-23-trihydroxystigmastan-6-one

Article	Year
Synergistic in vitro interactions between (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1. Chemotherapy, 2006, Volume: 52, Issue:1 The replication of herpes simplex virus (HSV) type 1 in Vero cells is inhibited in the presence of (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one (6b), a synthetic brassinosteroid derivative. Since a late step of virus multiplication is hindered by 6b, we performed studies of drug-drug combination with acyclovir (ACV) and foscarnet (FOS). It was determined that 6b would act synergistically with low concentrations of ACV and moderate concentrations of FOS against HSV. The best drug combination tested in this study resulted in an increase of 29.3 and 47.2% in antiviral activity for ACV (0.036 microM) and FOS (37.5 microM) in the presence of 14.8 and 6.9 microM of 6b, respectively. Topics: Acyclovir; Animals; Antiviral Agents; Cell Line; Cell Proliferation; Chlorocebus aethiops; Cholestanones; Drug Synergism; Foscarnet; Herpesvirus 1, Human; Molecular Structure	2006

Article

Year

Synergistic in vitro interactions between (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1.

Chemotherapy, 2006, Volume: 52, Issue:1

The replication of herpes simplex virus (HSV) type 1 in Vero cells is inhibited in the presence of (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one (6b), a synthetic brassinosteroid derivative. Since a late step of virus multiplication is hindered by 6b, we performed studies of drug-drug combination with acyclovir (ACV) and foscarnet (FOS). It was determined that 6b would act synergistically with low concentrations of ACV and moderate concentrations of FOS against HSV. The best drug combination tested in this study resulted in an increase of 29.3 and 47.2% in antiviral activity for ACV (0.036 microM) and FOS (37.5 microM) in the presence of 14.8 and 6.9 microM of 6b, respectively.

Topics: Acyclovir; Animals; Antiviral Agents; Cell Line; Cell Proliferation; Chlorocebus aethiops; Cholestanones; Drug Synergism; Foscarnet; Herpesvirus 1, Human; Molecular Structure

2006